(SLN) Silence Therapeutics plc Business Model Canvas Research

Phase I programs like SLN360 and SLN124 depend on specialist trial sites and investigators to enroll small cohorts, dose patients, monitor safety, and capture clean data. In early studies, even 20-60 patients can be enough to show human proof-of-concept, so site quality directly shapes speed, cost, and readout risk.

• Run enrollment and dosing
• Track safety in real time
• Capture high-quality trial data
• Support proof-of-concept reads

In 2025, Silence Therapeutics plc relied on CRO and CMC partners to run study management, analytics, and drug substance or drug product supply. This keeps fixed capex low for a clinical-stage biotech and shifts more work to specialists instead of building large in-house ops.

• CROs handle trials and data
• CMC partners supply materials
• Lower fixed infrastructure needs

Silence Therapeutics plc runs alliance management across 3 named partners, aligning target selection, milestones, and commercial terms so outside funding can back its siRNA pipeline. In 2025, this matters because partner-backed programs reduce internal spend and add third-party validation for clinical and deal execution.

• 3 partner alliances
• Shares development risk
• Links milestones to cash

Silence Therapeutics plc uses regulatory, IP, and CMC work to keep its siRNA programs on track for clinic and market entry. The company’s filings, patent moat, and manufacturing controls help protect platform value and strengthen licensing talks, because partners want clear data packages and a path to scalable supply.

• Regulatory docs support trial entry
• Patents protect platform IP
• CMC secures manufacturing readiness
• Stronger package boosts licensing power

Silence Therapeutics plc’s patent estate protects its RNAi design and targeting tools, while its 2025 preclinical and clinical data help prove the platform to partners. Together, IP plus data make the core asset that supports licensing talks and deal value.

• Protects RNAi design
• Supports targeting claims
• Boosts partner confidence

Silence Therapeutics plc relies on a small, high-skill scientific and regulatory team to pick RNA targets, run trials, and meet FDA and EMA rules. This work is central to execution quality and partner delivery, especially across its late-stage siRNA pipeline.

• RNA biology expertise drives target selection
• Clinical and regulatory staff run trials
• Supports partnership and filing delivery

Silence Therapeutics plc can co-develop or license programs with larger pharma groups, so it can reach more markets than a small biotech alone. This model also helps fund R&D, since partner cash can share trial costs and lower reliance on internal funding.

• Broader reach through pharma partners
• Shared development cost and risk
• Non-dilutive funding can support R&D

Silence Therapeutics plc’s value lies in a validated RNAi platform: the same gene-silencing class has 6 approved medicines, and GalNAc liver targeting boosts uptake in hepatocytes, improving delivery efficiency for liver-expressed disease targets. That makes the platform well suited to hard-to-treat targets where precise, liver-selective knockdown matters most.

• RNAi is clinically proven.
• GalNAc improves liver selectivity.
• Better delivery supports harder targets.

Silence Therapeutics plc needs tight, ongoing contact with trial sites and patients because recruitment, safety checks, and retention drive study speed and data quality. In clinical research, site and patient issues can consume 30%-40% of timelines, so clear communication and fast follow-up help keep studies on track.

• Support faster recruitment
• Strengthen safety oversight
• Reduce patient drop-off

Silence Therapeutics plc keeps investors informed with regular pipeline, partnership, and funding updates, which matters for a listed biotech that must support trial execution and future capital raises. Clear disclosure helps reduce uncertainty and keep access to the market open.

• Pipeline progress
• Partnership news
• Financing needs
• Supports market confidence

Silence Therapeutics plc uses its corporate website and investor relations page as the main channel for pipeline updates, corporate news, and regulated financial disclosures. For a London-listed biotech, this matters because investors need fast access to trial milestones, annual and interim results, and market-sensitive updates in one place.

• Pipeline and trial news
• Financial results and filings
• Direct investor access

Silence Therapeutics plc uses partner company networks to widen access to development, regulatory, and commercial channels beyond its own team. Existing alliances can speed clinical planning and market reach, so the model scales without building every capability in-house.

• Broader channel access through partners
• Support for development and regulation
• Commercial reach beyond internal footprint

Silence Therapeutics plc targets hematology and rare disease patients with SLN124 in non-transfusion-dependent thalassemia and myelodysplastic syndrome, plus planned work in polycythemia vera. These are small, high-need specialty groups where even modest clinical gains can matter a lot.

• 2 active SLN124 indications

• 1 planned polycythemia vera program

If Silence Therapeutics plc reaches market, payers and healthcare systems will shape access, uptake, and price, especially in rare disease care where treatment often faces strict prior-authorization and budget checks. Roughly 300 million people live with a rare disease worldwide, and reimbursement decisions can make or break launch speed and patient reach.

• Control access and pricing
• Key in rare disease markets
• Drive uptake after approval

Manufacturing and CMC are a heavy cost line for Silence Therapeutics plc because each trial needs drug substance production, formulation, and analytical testing. Oligonucleotide work also needs niche expertise and controlled quality systems, so costs usually step up as programs move from early studies to later stages.

In 2025, this meant higher external CMC spend tied to advancing RNAi assets and scaling GMP supply.

• Drug substance, formulation, testing
• Specialized oligonucleotide know-how
• Costs rise with each trial phase

Silence Therapeutics plc carries structural public-biotech overheads: legal, finance, London listing, patent filing and defense, plus partner deal work and regulatory compliance. These G&A and IP costs are recurring, and they rise with each program, because every assay, license, and disclosure needs contract, reporting, and protection work.

• Legal, finance, and listing fees recur
• IP protection is a core cash cost
• Partnerships add negotiation and compliance overhead

Silence Therapeutics plc can earn royalties if partnered products reach market, so revenue can scale without building a full sales force. In its latest reported results, that stream is still pre-commercial, which keeps the upside tied to partnered pipeline success rather than current product sales.

• Royalties = long-term upside
• No full commercial buildout needed
• Value capture depends on launches

Silence Therapeutics plc can monetize its siRNA platform by licensing target rights or broader platform access, then layering option fees so partners can reserve a program while preclinical or early clinical data mature. This is a standard RNAi deal shape: partners pay now for access, then more if they exercise rights or hit milestones.

• Licenses sell access to platform or targets.
• Options defer partner commitment.
• Common in early-stage RNAi assets.